Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 28;11(7):871. doi: 10.3390/antibiotics11070871

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Antimicrobial susceptibility of ceftazidime/avibactam (CZA)-resistant (n = 9) and CZA-susceptible (n = 13) P. aeruginosa isolates. Ceftolozane/tazobactam and CZA minimum inhibitory concentrations (MICs) were determined by gradient strips. Percentages of resistant and susceptible (standard dose and incremented exposure) isolates were calculated using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) v.10. 0 (2020) clinical breakpoints. TZP, piperacillin/tazobactam; ATM, aztreonam; CAZ, ceftazidime; FEP, cefepime; IPM, imipenem; MEM, meropenem; CIP, ciprofloxacin; GEN, gentamicin; TOB, tobramycin; AMK, amikacin; CST, colistin; CZA, ceftazidime/avibactam; CT, ceftolozane/tazobactam.